Indeed, due its cancer-selective pharmacology and capacity to bypass drug resistance and synergise with bortezomib, DTP3 represents a significant clinical opportunity, which could translate into a safe and effective anticancer therapeutic to treat patients with relapsed/refractory MM and potentially other recalcitrant NF-κB-driven cancers. Here, NFKB1 is linked to Miyoshi myopathy.